Abstract
Immunogenic cell death (ICD) is a type of cell death sparking adaptive immune responses that can reshape the tumor microenvironment. Exploring key ICD-related genes in bladder cancer (BLCA) could enhance personalized treatment. The Cancer Genome Atlas (TCGA) BLCA patients were divided into two ICD subtypes: ICD-high and ICD-low. High ICD expression linked to increased immune cell infiltration and longer survival, but with potentially suppressed immune function. The high ICD group responded better to PD1-targeted therapy. A risk-scoring model with four ICD-related genes (CALR, IL1R1, IFNB1, IFNG) was validated across TCGA, GEO datasets, and tissue samples, showing higher risk score correlated with weaker anti-tumor immune function, more tumor-promoting elements, lower immunotherapy response rates, and shorter patient survival. This study connects ICD-related genes to BLCA prognosis and immune infiltration, offering a vital tool for personalized treatment guidance.
Funding Information
  • National Natural Science Foundation of China (82303623)
  • Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0532300)
  • Shanghai Public Health Clinical Center (Intramural funding KY-GW-2025-01)
  • Open Project of Key Laboratory of Vascular Aging (HUST), Ministry of Education (VAME-2024-1)
  • National Key Research and Development Program of China (2019YFA0905600)
  • China Postdoctoral Science Foundation (2023M731199)
  • Hubei Provincial Department of Human Resources and Social Security (Postdoctoral Innovation Research Post 331048)
  • Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0525700)

This publication has 27 references indexed in Scilit: